Study finds GLP-1 prescriptions easily obtained via some telehealth sites
This story involves professional misconduct allegations. Any claims of wrongdoing described here are allegations, not established facts, unless a court or official body has ruled otherwise. This disclosure does not remove our responsibility for what's published below.
See sources Request a correction Report a serious problem / request takedown Corrections & takedown policy
AI-assisted synthesis, reviewed and approved by the editorial team. Generated , updated since first publication on as new sources were added. Approved by editorial team: .
A study of online healthcare platforms found that many offer GLP-1 weight-loss medications with minimal clinician oversight. Researchers were able to obtain prescriptions in under five minutes using fake patient profiles.
Amalgamated from The Hill (opens in new tab), STAT News (opens in new tab), STAT News (opens in new tab)
A study involving "secret shoppers" has found that GLP-1 weight-loss medications can be obtained through various telehealth platforms with minimal clinician interaction. Researchers from Yale University and other participants used fake patient profiles to test the systems, aiming to determine how easily prescriptions could be secured without rigorous medical oversight.
According to reports from The Hill, some researchers successfully obtained prescriptions in under five minutes. These instances were conducted using fabricated identities, which allowed the study to measure the speed and simplicity of the process across different online platforms. The findings indicate that in certain cases, the transition from a patient's request to an issued prescription was nearly instantaneous.
STAT News also reports that these telehealth sites often do not provide what is described as appropriate clinical care for GLP-1 medications. The "secret shopper" methodology allowed researchers to observe and document where medical oversight might be bypassed or minimized in the digital environment. By using anonymous personas, the study was able to highlight discrepancies between standard medical practices and the procedures used by some online providers.
The results are being examined as the market for GLP-1 medications continues to expand globally. While these drugs provide significant treatment options for obesity and type 2 diabetes, the ease of access through certain online portals has raised questions regarding the regulation of telehealth services and the consistency of patient safety protocols in the digital healthcare sector.
Why this matters
The findings highlight concerns regarding the regulation and safety of weight-loss drugs distributed through digital health platforms. The results may prompt closer scrutiny of how telehealth companies vet patients for GLP-1 treatments and whether current oversight is sufficient to ensure patient safety.
What's confirmed / what isn't
Multiple independent sources confirm that the study utilized 'secret shoppers' and fake profiles to test telehealth platforms. The specific finding of prescriptions being issued in under five minutes is attributed to reporting from *The Hill*, while the lack of appropriate clinical care is reported by *STAT News*.
Background
GLP-1 (glucagon-like peptide-1) medications, such as semaglutide or tirzepatide, are a class of drugs used primarily to manage weight and treat type 2 diabetes.